We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
News

IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision

IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
News

IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IPSOGEN SAS has announced the signature of a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.

The Genomic Grade™ is a genomic index invented by Pr. Christos Sotiriou & Pr. Martine Piccart, from the Bordet Institute, Brussels and Dr. Mauro Delorenzi from the Swiss Institute for Cancer Research (ISREC), Lausanne, two European cancer research institutes.

In their seminal paper published in 2006 in the Journal of the National Cancer Institute, Pr. Sotiriou & colleagues showed that the grade, as measured today and since 1890 by histological examination of tumor sections under a microscope, could not describe the proliferation ability of 30 to 60 % of tumors.

By contrast, the Genomic Grade™ could capture proliferation in most tumors and showed superior prognostic & classification value over conventional grading methods. These findings have been validated in more than 1’100 patients, including a second study published last year in the Journal of Clinical Oncology.

The Genomic Grade™ represents the common core feature of the main breast cancer prognostic genomic signatures published worldwide, as shown by a meta-analysis presented by Pr. Piccart at the St. Gallen Breast Cancer conference in March 2007.

Importantly, the Genomic Grade™ can be measured by both DNA microarray and multiplex PCR technologies, as presented at the 2007 meeting of the American Society of Clinical Oncology.

Advertisement